Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PDE9A | O76083 | 2/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | PDE1A | P54750 | 3/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.37 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.37 |
| ▸ | NT5E | P21589 | 7/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17357047 | 0.96 | LMNA (0.48) | YTHDC1ALDH1A1LMNAPOLBPDE9A | |
| SCHEMBL26633649 | 0.89 | YTHDC1 (0.39) | YTHDC1ALDH1A1LMNAPOLBPDE9A | |
| SCHEMBL12398418 | 0.87 | YTHDC1 (0.47) | YTHDC1ALDH1A1LMNAPOLBPDE9A | |
| SCHEMBL31252616 | 0.87 | ALDH1A1 (0.48) | YTHDC1ALDH1A1LMNAPOLBPDE9A | |
| SCHEMBL166297 | 0.87 | ALDH1A1 (0.42) | YTHDC1ALDH1A1LMNAPOLBPDE9A | |
| SCHEMBL24174539 | 0.85 | YTHDC1 (0.60) | YTHDC1ALDH1A1LMNAPOLBNT5E | |
| SCHEMBL23828455 | 0.85 | YTHDC1 (0.48) | YTHDC1ALDH1A1LMNAPOLBPDE9A | |
| SCHEMBL14752430 | 0.85 | YTHDC1 (0.43) | YTHDC1ALDH1A1LMNAPOLBPDE9A | |
| SCHEMBL23660759 | 0.84 | YTHDC1 (0.42) | YTHDC1ALDH1A1LMNAPOLBPDE9A | |
| SCHEMBL31158338 | 0.84 | YTHDC1 (0.42) | YTHDC1ALDH1A1LMNAPOLBPDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117683033-B | Substituted alkynyl heterocyclic compounds | Capital Pharmaceutical Holdings (Beijing) Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-20250257070-A1 | NOVEL SULFONAMIDE DERIVATIVE WITH FUSED PYRIMIDINE SKELETON, HAVING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION INHIBITORY EFFECT | HANMI PHARM. CO., LTD. (KR) | 2025-08-14 | — | — | US | disclosed |
| EP-4592286-A1 | MACROCYCLIC NITROGEN-CONTAINING CROWN ETHER COMPOUND AND USE THEREOF AS PROTEIN KINASE INHIBITOR | Artivila Biopharma (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-12319695-B2 | Sulfonamide derivative with fused pyrimidine skeleton, having epidermal growth factor receptor mutation inhibitory effect | HANMI PHARM. CO., LTD. (KR) | 2025-06-03 | — | — | US | disclosed |
| CN-120020133-A | Nitrogen-containing heterocyclic derivative and medical application thereof | 杭州百新生物医药科技有限公司 | 2025-05-20 | — | — | CN | disclosed |
| WO-2025096490-A1 | UBIQUITIN SPECIFIC PROCESSING PROTEASE 1 (USP1) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096487-A1 | UBIQUITIN SPECIFIC PROCESSING PROTEASE 1 (USP1) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| US-12264161-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-113880842-B | Substituted alkynyl heterocyclic compounds | 首药控股(北京)股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119060060-A | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20090192176-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090192176-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-30 | — | — | US | disclosed |
| WO-2009052145-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052145-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009032694-A1 | AMINO SUBSTITUTED PYRIMIDINE, PYROLLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS AND IN TREATING PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | DANA FARBER CANCER INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032694-A1 | AMINO SUBSTITUTED PYRIMIDINE, PYROLLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS AND IN TREATING PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | DANA FARBER CANCER INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032703-A1 | 2- (HET) ARYLAMINO-6-AMINOPYRIDINE DERIVATIVES AND FUSED FORMS THEREOF AS ANAPLASTIC LYMPHOMA KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032703-A1 | 2- (HET) ARYLAMINO-6-AMINOPYRIDINE DERIVATIVES AND FUSED FORMS THEREOF AS ANAPLASTIC LYMPHOMA KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192176-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PIK3CA, PIK3CD | YTHDC1 619/4885ALDH1A1 3052/4885LMNA 3803/4885 |
| US-12319695-B2 | Sulfonamide derivative with fused pyrimidine skeleton, having epidermal growth factor receptor mutation inhibitory effect | EGFR, FGFR1, FGFR3 | YTHDC1 2436/4885ALDH1A1 3515/4885LMNA 4573/4885 |
| US-20250257070-A1 | NOVEL SULFONAMIDE DERIVATIVE WITH FUSED PYRIMIDINE SKELETON, HAVING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION INHIBITORY EFFECT | EGFR, FGFR1, FGFR3 | YTHDC1 2620/4885ALDH1A1 3055/4885LMNA 4590/4885 |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PIK3CD | YTHDC1 3380/4885ALDH1A1 2453/4885LMNA 4796/4885 |
| US-12264161-B2 | Heterocyclic adenosine receptor antagonists | ADORA2A, ADORA1, ADORA3 | YTHDC1 3606/4885ALDH1A1 789/4885LMNA 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.